Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174028 | 0.88 | HTR2A (0.47) | KIF11HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL15389721 | 0.88 | HTR2A (0.47) | KIF11HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL175744 | 0.88 | HTR2A (0.47) | KIF11HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL173679 | 0.84 | HTR2A (0.38) | HTR2AHTR2CMEN1KMT2ADRD2 | |
| SCHEMBL174815 | 0.81 | HTR2A (0.40) | HTR2AHTR2CMEN1KMT2ADRD2 | |
| SCHEMBL173574 | 0.81 | HTR2A (0.39) | HTR2AHTR2CMEN1KMT2ADRD2 | |
| SCHEMBL175131 | 0.74 | HTR2A (0.40) | HTR2AHTR2CMEN1KMT2ADRD2 | |
| SCHEMBL174416 | 0.74 | HTR2A (0.40) | HTR2AHTR2CMEN1KMT2ADRD2 | |
| SCHEMBL173622 | 0.74 | HTR2A (0.57) | HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL175226 | 0.72 | SLC13A5 (0.36) | HTR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |